IN8BIO, INC. Logo

IN8BIO, INC.

Clinical-stage biopharma developing gamma-delta T cell therapies for cancer.

INAB | US

Overview

Corporate Details

ISIN(s):
US45674E1091
LEI:
Country:
United States of America
Address:
EMPIRE STATE BUILDING, 10118 NEW YORK

Description

IN8BIO, INC. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell therapies for solid and hematological tumors. The company's proprietary DeltEx™ platform utilizes allogeneic, autologous, and genetically modified approaches to develop novel cell therapies. IN8BIO was the first to advance genetically modified gamma-delta T cells into clinical trials. Its lead product candidates include INB-400, a Phase 2 asset for newly diagnosed glioblastoma (GBM), and INB-100, a Phase 1 candidate for patients with leukemia undergoing hematopoietic stem cell transplantation. The company is also advancing a broad portfolio of preclinical programs focused on solid tumors.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2024-12-15
English
4.2 MB
2024-10-30
German
1.8 MB
2024-08-14
French
0.5 MB
2024-05-22
English
2.1 MB
2024-03-10
English
3.5 MB
2024-01-15
German
1.2 MB
2023-11-20
English
5.1 MB

Full Filing History Restricted

Access to specific historical documents or filtered results is limited in the Web UI. Request access to the complete dataset.

Automate Your Workflow. Get a real-time feed of all IN8BIO, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for IN8BIO, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for IN8BIO, INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Cessatech A/S Logo
A biotech company developing medicines for children's acute pain management.
Denmark
CESSA
CG Invites Co., Ltd. Logo
A biopharmaceutical company specializing in digital genomics and personalized medicine.
South Korea
083790
CG Oncology, Inc. Logo
Develops bladder-sparing oncolytic immunotherapies for urologic cancers.
United States of America
CGON
CHA Vaccine Research Institute Logo
Develops vaccines and immunotherapeutics using proprietary adjuvant platforms.
South Korea
261780
Develops and manufactures veterinary medicines and functional feed additives.
South Korea
052670
Chemical Works of Gedeon Richter Plc Logo
Vertically integrated pharma company focused on women's health and other therapies.
Hungary
RICHT
Chemomab Therapeutics Ltd. Logo
Clinical-stage biotech developing therapeutics for fibro-inflammatory diseases.
United States of America
CMMB
CHINA PHARMA HOLDINGS, INC. Logo
Develops, manufactures, and markets prescription, OTC, and nutritional products.
United States of America
CPHI
China SXT Pharmaceuticals, Inc. Logo
Researches, develops, manufactures, and sells traditional Chinese medicine products.
United States of America
SXTC
ChoA Pharmaceutical Co., LTD. Logo
Develops, manufactures, and sells pharmaceutical products and health supplements.
South Korea
034940

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.